GNPX - Genprex wins FDA orphan drug designation for lead asset
2023-08-10 08:30:12 ET
More on Genprex
- Genprex gets safety panel nod to proceed in lung cancer study of Reqorsa
- Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer
- Genprex begins patient enrollment in Phase 1/2 trial testing lung cancer therapy
For further details see:
Genprex wins FDA orphan drug designation for lead asset